- Home
- GYRE vs GNK Comparison
GYRE vs GNK Comparison
Compare GYRE & GNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GYRE | GNK |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.7M | 849.7M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | GYRE | GNK |
|---|---|---|
| Price | $8.01 | $20.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $17.00 | ★ $19.00 |
| AVG Volume (30 Days) | 77.3K | ★ 335.7K |
| Earning Date | 03-16-2026 | 02-17-2026 |
| Dividend Yield | N/A | ★ 7.15% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | $107,265,000.00 | ★ $331,332,000.00 |
| Revenue This Year | $11.59 | N/A |
| Revenue Next Year | $26.31 | $10.38 |
| P/E Ratio | $205.16 | ★ N/A |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $6.11 | $11.20 |
| 52 Week High | $13.75 | $20.68 |
Technical Indicators
Market Signals| Indicator | GYRE | GNK |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 65.89 |
| Support Level | $7.78 | $19.82 |
| Resistance Level | $8.17 | $20.68 |
| Average True Range (ATR) | 0.30 | 0.58 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 46.14 | 74.35 |
Price Performance
Historical ComparisonAbout GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About GNK Genco Shipping & Trading Limited New (Marshall Islands)
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.